Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATRA NASDAQ:GNTA NASDAQ:IRD NASDAQ:MRKR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATRAAtara Biotherapeutics$11.55+0.3%$9.16$5.01▼$18.70$68.84M0.2668,241 shs39,781 shsGNTAGenenta Science$3.73-3.2%$3.83$2.74▼$7.28$68.15M0.626,291 shs3,029 shsIRDOpus Genetics$1.07-3.6%$1.04$0.65▼$1.86$63.84M0.01233,623 shs139,975 shsMRKRMarker Therapeutics$1.35-3.6%$1.53$0.95▼$5.95$15.28M1.453.47 million shs176,676 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATRAAtara Biotherapeutics0.00%-0.26%+44.19%+59.31%+27.34%GNTAGenenta Science0.00%-2.18%-3.70%-10.65%-7.54%IRDOpus Genetics0.00%-9.32%+7.00%+12.93%+106,999,900.00%MRKRMarker Therapeutics0.00%-13.46%-14.34%+9.76%-69.25%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATRAAtara Biotherapeutics3.7975 of 5 stars3.41.00.04.70.63.30.6GNTAGenenta Science1.9428 of 5 stars3.53.00.00.01.11.70.0IRDOpus Genetics1.1922 of 5 stars3.50.00.00.00.00.00.6MRKRMarker Therapeutics4.1593 of 5 stars3.85.00.03.91.10.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATRAAtara Biotherapeutics 2.83Moderate Buy$20.0073.16% UpsideGNTAGenenta Science 3.00Buy$25.00570.96% UpsideIRDOpus Genetics 3.00Buy$7.33585.36% UpsideMRKRMarker Therapeutics 3.50Strong Buy$13.17875.31% UpsideCurrent Analyst Ratings BreakdownLatest MRKR, IRD, GNTA, and ATRA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/27/2025IRDOpus GeneticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00(Data available from 8/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATRAAtara Biotherapeutics$128.94M0.53N/AN/A($16.89) per share-0.68GNTAGenenta ScienceN/AN/AN/AN/A$0.74 per shareN/AIRDOpus Genetics$10.99M5.81N/AN/A$0.21 per share5.10MRKRMarker Therapeutics$6.59M2.32N/AN/A$1.73 per share0.78Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATRAAtara Biotherapeutics-$85.40M-$3.72N/AN/AN/A-7.83%N/A-14.51%8/11/2025 (Estimated)GNTAGenenta Science-$9.64MN/A0.00N/AN/AN/AN/AN/AN/AIRDOpus Genetics-$57.53M-$2.10N/AN/AN/A-429.42%-283.28%-144.32%8/12/2025 (Estimated)MRKRMarker Therapeutics-$10.73M-$1.33N/AN/AN/A-224.46%-101.87%-83.02%8/13/2025 (Estimated)Latest MRKR, IRD, GNTA, and ATRA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025MRKRMarker Therapeutics-$0.55N/AN/AN/A$0.72 millionN/A8/12/2025N/AIRDOpus Genetics-$0.25N/AN/AN/A$4.27 millionN/A8/11/2025Q2 2025ATRAAtara Biotherapeutics-$0.32N/AN/AN/A$4.23 millionN/A5/15/2025Q1 2025ATRAAtara Biotherapeutics-$3.07$3.50+$6.57$3.50$4.30 million$98.10 million5/15/2025Q1 2025IRDOpus Genetics-$0.34-$0.32+$0.02-$0.24$4.00 million$4.30 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATRAAtara BiotherapeuticsN/AN/AN/AN/AN/AGNTAGenenta ScienceN/AN/AN/AN/AN/AIRDOpus GeneticsN/AN/AN/AN/AN/AMRKRMarker TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATRAAtara BiotherapeuticsN/A0.570.57GNTAGenenta ScienceN/A6.896.89IRDOpus GeneticsN/A1.981.98MRKRMarker TherapeuticsN/A6.796.79Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATRAAtara Biotherapeutics70.90%GNTAGenenta Science15.13%IRDOpus Genetics14.97%MRKRMarker Therapeutics22.39%Insider OwnershipCompanyInsider OwnershipATRAAtara Biotherapeutics4.00%GNTAGenenta Science28.99%IRDOpus Genetics6.60%MRKRMarker Therapeutics14.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATRAAtara Biotherapeutics3305.96 million5.72 millionOptionableGNTAGenenta Science718.29 million12.99 millionNot OptionableIRDOpus Genetics1459.66 million55.72 millionN/AMRKRMarker Therapeutics6011.32 million9.67 millionNot OptionableMRKR, IRD, GNTA, and ATRA HeadlinesRecent News About These CompaniesMarker Therapeutics to Participate in a Fireside Chat at the Canaccord Genuity 45th Annual Growth ConferenceJuly 30, 2025 | globenewswire.comMarker Therapeutics Insider Trading Activity | NASDAQ:MRKR | BenzingaJuly 18, 2025 | benzinga.comHere's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn SituationJuly 11, 2025 | finance.yahoo.comMarker Therapeutics and Cellipont Bioservices Announce Collaboration to Advance cGMP Manufacturing of MT-601, a Multi-Antigen Recognizing T Cell Therapy for Patients with LymphomaJune 17, 2025 | globenewswire.comMarker Therapeutics Reports that Lymphodepletion Improves the Expansion and Persistence of Multi-Antigen Recognizing T Cells in Patients with LymphomaMay 20, 2025 | globenewswire.comMarker Therapeutics to Spotlight Multi-Antigen Recognizing (MAR)-T Cells in High-Profile Panel on CAR-T Cell TherapiesMay 19, 2025 | globenewswire.comArkansas Historic Preservation Program hosts National Historic Marker WeekendApril 17, 2025 | stuttgartdailyleader.comSMarker Therapeutics (MRKR) Receives a Buy from Canaccord GenuityApril 1, 2025 | markets.businessinsider.comMarker Therapeutics to Present at Canaccord Genuity’s Horizons in Oncology ConferenceApril 1, 2025 | markets.businessinsider.comMarker Therapeutics to Present at Canaccord Genuity's Horizons in Oncology ConferenceApril 1, 2025 | globenewswire.comMarker Therapeutics reports FY24 EPS ($1.19) vs ($1.59) last yearMarch 31, 2025 | markets.businessinsider.comMarker Therapeutics Reports Year-End 2024 Corporate and Financial ResultsMarch 31, 2025 | globenewswire.comMarker Therapeutics stockholder vote clears warrant issuanceMarch 28, 2025 | investing.comMarker Therapeutics initiated with a Buy at CanaccordMarch 5, 2025 | markets.businessinsider.comCanaccord Genuity Initiates Coverage of Marker Therapeutics (MRKR) with Buy RecommendationMarch 5, 2025 | msn.comMarker Therapeutics, Inc. CEO Juan Vera to Present at H.C. Wainwright 3rd Annual Cell Therapy Virtual ConferenceFebruary 25, 2025 | quiverquant.comQMarker Therapeutics to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual ConferenceFebruary 25, 2025 | globenewswire.comMRKR stock touches 52-week low at $1.61 amid market challengesFebruary 12, 2025 | msn.comBrookline Capital sets $4 target on Marker Therapeutics stockFebruary 11, 2025 | msn.comMarker Therapeutics initiated with a Buy at BrooklineFebruary 11, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military Spend3 Short Squeeze Candidates With Big Catalysts on the HorizonBy Dan Schmidt | July 25, 2025View 3 Short Squeeze Candidates With Big Catalysts on the HorizonAmerica Wants Drone Dominance: Are These Stocks Ready to Soar?By Chris Markoch | July 20, 2025View America Wants Drone Dominance: Are These Stocks Ready to Soar?Super Micro Computer Sees Unusual Volume—Catalyst Ahead?By Gabriel Osorio-Mazilli | July 25, 2025View Super Micro Computer Sees Unusual Volume—Catalyst Ahead?Could Dutch Bros Dethrone Starbucks? Why Investors Are Perking UpBy Jordan Chussler | July 7, 2025View Could Dutch Bros Dethrone Starbucks? Why Investors Are Perking UpMRKR, IRD, GNTA, and ATRA Company DescriptionsAtara Biotherapeutics NASDAQ:ATRA$11.55 +0.03 (+0.26%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$11.50 -0.04 (-0.39%) As of 08/1/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.Genenta Science NASDAQ:GNTA$3.73 -0.12 (-3.22%) As of 08/1/2025 03:39 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. In addition, it develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. Genenta Science S.p.A. was incorporated in 2014 and is headquartered in Milan, Italy.Opus Genetics NASDAQ:IRD$1.07 -0.04 (-3.60%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.08 +0.01 (+0.93%) As of 08/1/2025 04:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Opus Genetics Inc. is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc., formerly known as Ocuphire Pharma Inc., is based in Farmington Hills, Michigan.Marker Therapeutics NASDAQ:MRKR$1.35 -0.05 (-3.57%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.15 -0.20 (-15.11%) As of 08/1/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale Is PG&E an AI Power Play? Why Options Traders Are Betting Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
